Baxter has settled on a name for its $4.5 billion kidney care division, which is slated to strike out on its own as an independent portfolio of dialysis machines, acute renal therapies and services.

Baxter International’s plans to streamline its operations are taking a big step with the proposed $3.8 billion sale of its kidney care business to private equity firm The Carlyle Group. The two ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx ...

Baxter International says it's achieved a 25% lower mortality risk for up to four years in hemodialysis patients in a study of its new therapy. In a 48-month study of 1,092 dialysis patients, Baxter's ...

On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) ...

Please provide your email address to receive an email when new articles are posted on . Baxter agrees to divest its kidney care business to investor group Carlyle for $3.8 billion. Carlyle has been a ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Private-equity firm Carlyle Group is in talks to buy ...

Baxter Highlights New Data at Kidney Week Indicating Sharesource Is Associated With a 77% Lower Risk of Home Dialysis Technique Failure Additional key data presented at the congress indicates how HDx ...

Please provide your email address to receive an email when new articles are posted on . Baxter International plans to spin off its renal care and acute therapies global business units into an ...

Baxter put forward clinical data showing that its expanded hemodialysis approach, which aims to filter out a greater range of harmful molecules from the bloodstream, was able to help reduce the number ...